Regulatory approval for the anti-programmed death 1 (PD-1) receptor monoclonal antibody (mAb) pembrolizumab represented a major therapeutic advance for patients with metastatic solid cancers . As anticipated, immune checkpoint blockade of the PD-1/programmed death-ligand 1 (PD-L1) axis leads to unchecked immune responses and the development of autoimmune manifestations, referred to as immune-related adverse events (irAEs) . Herein, we report a patient with metastatic urothelial carcinoma treated with pembrolizumab who developed fatal polymyositis (PM).
A patient with pembrolizumab-induced fatal polymyositis
Leggi l'articolo originale